{"disease":{"id":"psoriatic-dermatitis","name":"psoriatic dermatitis"},"drugs":{"marketed":[{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}